Pre-Conference Focus Day, 30th January, 2024
8:30 am Registration and Networking
8:59 am
Expanding Microbiome Therapeutic Development Beyond the Gut to Improve the Lives of Patients in Need
9:20 am Chair’s Opening Remarks
9:29 am
EXPLORING THE MICROBIOME IN WOMEN’S HEALTH & FERTILITY TO UNDERPIN RESEARCH & CLINICAL DEVELOPMENT
9:30 am Revealing a Donor-Derived Microbiome Product for Infectious Disease Beyond the Gut
Synopsis
- Developing a donor-derived, cGMP manufactured oral capsule according to regulatory compliance.
- Outlining MVT-201: a microbiome-derived therapeutic product to eradicate MDR-bacteria from the reservoir, beyond gut infections.
- Exploring safety and efficacy of MVT-201 in infectious diseases murine modes
10:00 am Developing Microbial Immunotherapies for Women’s Health
Synopsis
- Exploring the vaginal microbiome and its role in female reproductive health
- Outlining the vaginal microbiome and immune activation in the female reproductive tract
- Assessing clinical translation and the therapeutic potential to leverage microbial immunotherapies in women’s health
10:30 am Gut Micro- & Mycobiota in Pre-eclampsia: Bacterial Composition Differences Suggest Role in Pathophysiology
Synopsis
- Exploring changes in fungal diversity
- Outlining a potential link between fungi and immune changes in pregnancy
- Suggesting a role in the pathophysiology of PE
11:00 am Panel Discussion: Representation for Women: Innovation & Investment for Women’s Health LBP Research & Development
Synopsis
- Addressing the huge unmet medical needs in women across bacterial vaginosis, vulvovaginal candidiasis, post-menopausal recurrent urine infections, polycystic ovary syndrome & beyond
- Discussing the huge market potential for such research and development
- Outlining how we can push investment and innovation in the space and which areas need to be targeted
11:30 am Morning Break & Networking
11:59 am
UNDERSTANDING THE LUNG MICROBIOME TO UNCOVER NOVEL THERAPEUTIC TARGETS & FUTURE CLINICAL APPLICATIONS
12:00 pm Engineering Live Biotherapeutics to Expose Antigens or Deliver Therapeutic Agents to Treat Complex Respiratory Diseases
Synopsis
- Utilising a unique genetic toolkit to engineer the genome of a minimal cell lung bacteria, MycoChassis
- Developing a pipeline of products to treat diseases that require the combination of different MoAs
- Outlining pre-clinical results showing efficacy and safety for both biofilm associated infections pipeline as well as lead product designed to treat non-small cell lung carcinoma (NSCLC) patients that don’t respond to immunotherapy
12:30 pm Uncovering the Role of the Microbiome in Chronic Lung Disease
Synopsis
- Discussing functional roles played by the respiratory microbiome in healthy homeostasis
- Describing how airway microbiome perturbations contribute to disease pathogenesis in chronic lung disease
- Revealing the potential for microbiome manipulation as a novel treatment for chronic lung diseases
1:00 pm Lunch Break & Networking
1:59 pm
CANCER & THE MICROBIOME: UNCOVERING FURTHER MECHANISTIC DATA TO ENHANCE OUR UNDERSTANDINGS
2:00 pm Enabling Immunotherapy Responses in Solid Tumours Through Engineered Microbial Based Therapeutics
Synopsis
- Treating immunotherapy non-responders by targeting the extracellular matrix which acts as a physical barriers to effective immune infiltration to the tumour core
- Harnessing tumour colonising bacteria to locally disrupt the tumour extracellular matrix from within
- Adopting bacterial engineering approaches
2:30 pm Uncovering a Glycopeptide-mediated T-cell Immunotherapy to Modulate Anti-tumour Immunity
Synopsis
- Showing the effect of delivery of glycopeptide conjugates to steer a multi-targeted, yet tumour-specific, T-cell response in epithelial cancer
- Revealing novel mechanism of action to uncover efficacy data
- Reviewing new abstract and data presented at the recent American Society of Clinical Oncology Conferences (ASCO)
3:00 pm Afternoon Break & Networking
3:30 pm Panel Discussion: The Future of Microbiome Therapeutics as Co-therapies: Investment & Development Considerations
Synopsis
- Exploring the therapeutic potential for microbiome co-therapies
- Identifying health areas to have the most impact
- Outlining funding prospects and investor considerations
4:15 pm Roundtable: Dive into Discussions to Explore Your Topic of Interest
Synopsis
- Women’s health – what challenges still remain in developing LBPs to target women’s health disorders?
- Microbiome biomarkers – what is the next step in using analytical data for biomarkers? How could this be leveraged into clinical trials?
- Skin microbiome – where do we see the future of topical LBPs?